Baird lowered Qiagen (NYSE:Goggle) and Bio-Techne (Nasdaq:Only) From Leaprali to neutral, NIH financing and the shortcomings of the income of companies from this agency and from neutral.
Investment Bank reduced the price target for qiagen to $ 52 (~ 5% sub-top) to $ 42
